Physician profile
Katie Geiser
NPI 1013648591
$1,853.07
in general payments reported to CMS, 2019-2025
21 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $382 · 2023: $681 · 2024: $533 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $285.11 | 2022-2025 | |
| Boston Scientific Corporation | $250.59 | 2022-2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $200.80 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $162.66 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $158.52 | 2022-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $128.33 | 2022-2023 | Opsumit, Uptravi |
| Amgen INC. | $89.42 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $74.08 | 2022-2023 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Inspire Medical Systems, INC. | $72.10 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $57.02 | 2022-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.61 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $51.71 | 2022 | |
| Abbott Laboratories | $44.90 | 2024-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $43.09 | 2023-2024 | Verquvo |
| Cvrx, INC. | $38.60 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $37.14 | 2023 | Kcentra |
| Kiniksa Pharmaceuticals, Ltd. | $29.18 | 2022-2023 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $25.85 | 2022-2023 | Farxiga |
| Abiomed | $18.95 | 2024 | Impella |
| Novo Nordisk INC | $15.73 | 2022 | |
| Lilly USA, LLC | $13.68 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Geiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.